Apellis Pharmaceuticals Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Apellis Pharmaceuticals sono diminuiti a un tasso medio annuo di -5%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 19.1%. I ricavi sono cresciuti crescere a un tasso medio annuo di 50.4%.

Informazioni chiave

-5.0%

Tasso di crescita degli utili

7.5%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	17.0%
Tasso di crescita dei ricavi	50.4%
Rendimento del capitale proprio	-105.5%
Margine netto	-35.0%
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?

Jul 12

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

May 30

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

May 30

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

May 14

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Feb 16

With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

Jul 19

Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

May 13

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?

Apr 18

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt Sensibly?

Dec 14

Ripartizione dei ricavi e delle spese

Come Apellis Pharmaceuticals guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGS:APLS Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	715	-250	521	0
30 Jun 24	629	-333	545	0
31 Mar 24	524	-417	528	0
31 Dec 23	397	-529	501	0
30 Sep 23	273	-606	443	0
30 Jun 23	185	-657	376	0
31 Mar 23	106	-691	328	0
31 Dec 22	75	-652	277	0
30 Sep 22	113	-634	234	346
30 Jun 22	97	-638	202	296
31 Mar 22	81	-702	187	346
31 Dec 21	67	-746	177	0
30 Sep 21	256	-520	180	0
30 Jun 21	251	-460	171	50
31 Mar 21	251	-360	150	0
31 Dec 20	251	-345	139	300
30 Sep 20	1	-536	122	-142
30 Jun 20	0	-470	104	-91
31 Mar 20	0	-423	88	-40
31 Dec 19	0	-305	67	0
30 Sep 19	0	-228	46	173
30 Jun 19	0	-194	34	152
31 Mar 19	0	-156	27	128
31 Dec 18	0	-128	23	0
30 Sep 18	0	-109	21	88
30 Jun 18	0	-85	17	68
31 Mar 18	0	-64	13	50
31 Dec 17	0	-51	10	40
30 Sep 17	0	-39	7	33
30 Jun 17	0	-35	6	29
31 Mar 17	0	-30	5	25
31 Dec 16	0	-27	4	23
30 Sep 16	0	-29	6	21
30 Jun 16	0	-53	7	19
31 Mar 16	0	-50	7	16
31 Dec 15	0	-47	6	14
30 Sep 15	0	-41	4	12
30 Jun 15	0	-12	4	10
31 Mar 15	0	-12	3	9
31 Dec 14	0	-11	3	8

Guadagni di qualità: APLS al momento non è redditizia.

Margine di profitto in crescita: APLS al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: APLS non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 5% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di APLS nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: APLS non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 16.6% ).

Rendimento del capitale proprio

ROE elevato: APLS ha un Return on Equity negativo ( -105.47% ), in quanto al momento non è redditizio.

Apellis Pharmaceuticals Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Consensus EPS estimates fall by 24%

Price target decreased by 18% to US$51.79

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study

Apellis Pharmaceuticals, Inc. Presents Positive Results from the Phase 3 VALIANT Study at Kidney Week

Price target decreased by 7.0% to US$63.11

Would Apellis Pharmaceuticals (NASDAQ:APLS) Be Better Off With Less Debt?

Forecast breakeven date pushed back to 2026

Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion

Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues

Apellis: Rare Kidney Disease Data Leads To Possible First To Market

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

Price target decreased by 7.6% to US$69.12

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 11%

Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?

Independent Director notifies of intention to sell stock

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

Consensus EPS estimates fall by 17%

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 18%

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency

Consensus EPS estimates upgraded to US$0.98 loss

Consensus EPS estimates upgraded to US$1.00 loss

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Chief Technical Operations Officer recently sold US$646k worth of stock

Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024

Consensus EPS estimates fall by 13%, revenue upgraded

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application

Co-Founder notifies of intention to sell stock

Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer

Co-Founder recently sold US$525k worth of stock

Price target increased by 9.0% to US$71.44

Price target decreased by 9.6% to US$66.69

Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

Apellis Pharmaceuticals, Inc. and Sobi Presents Post Hoc Data that Reinforce the Long-Term Efficacy and Safety of EMPAVELI

CFO & Treasurer exercised options and sold US$633k worth of stock

Insufficient new directors

Apellis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Apellis Pharmaceuticals, Inc. Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

Apellis Pharmaceuticals, Inc. Receives Permanent J-Code (J2781) for SYFOVRE® (Pegcetacoplan Injection), Effective October 1, 2023

Levi & Korsinsky, LLP Notifies Investors in Apellis Pharmaceuticals, Inc. of Class Action Securities Lawsuit

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE (Pegcetacoplan Injection)

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc

No longer forecast to breakeven

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Apellis Pharmaceuticals, Inc. Provides Update on Review of Rare Safety Events with SYFOVRE® for Geographic Atrophy

Price target decreased by 9.8% to US$93.23

With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

New minor risk - Share price stability

General Counsel notifies of intention to sell stock

Chief People Officer notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

Consensus revenue estimates increase by 57%, EPS downgraded

Price target increased by 12% to US$100